What is Neurocrine Biosciences's gain/loss on asset sales?

Neurocrine Biosciences (NBIX) reported gain/loss on asset sales of $28.60M in Q1 2026.

What does gain/loss on asset sales mean?

The accounting adjustment that removes non-cash gains or losses from asset sales to show true operational cash flow.

Operating

Gain/Loss on Asset Sales

Analysis

StatementCash Flow Statement

SectionOperating

CategoryProfitability

SignalContext dependent

VolatilityVolatile

First reportedQ1 2025

Last reportedQ1 2026May 5, 2026

How to read this metric

A significant gain may indicate successful capital recycling, while recurring losses could signal asset impairment or poor investment decisions.

Detailed definition

This metric represents the non-cash accounting adjustment reflecting the difference between the carrying value and the p...

Peer comparison

Commonly found in the operating section of the cash flow statement across all capital-intensive industries, often labeled as 'Gain/Loss on disposal of assets'.

Metric ID: gain_loss_on_sale_of_assets_cf

Historical Data

2 periods

	Q1 '25	Q1 '26
Value	$0.00	$28.60M

Range$0.00 – $28.60M

Gain/Loss on Asset Sales at Other Companies

IQVIAIQV View metric

Frequently Asked Questions

What is Neurocrine Biosciences's gain/loss on asset sales?: Neurocrine Biosciences (NBIX) reported gain/loss on asset sales of $28.60M in Q1 2026.
What does gain/loss on asset sales mean?: The accounting adjustment that removes non-cash gains or losses from asset sales to show true operational cash flow.